These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22516052)

  • 1. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
    Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
    Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
    Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
    Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
    Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
    Tian Y; Zhang J; Yan S; Qiu L; Li Z
    Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.
    Xu X; Han L; Duan L; Zhao Y; Yang H; Zhou B; Ma R; Yuan R; Zhou H; Liu Z
    Br J Clin Pharmacol; 2013 Feb; 75(2):516-23. PubMed ID: 22804784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
    Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
    J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
    Kumpiro S; Sriuranpong V; Areepium N
    Asian Pac J Cancer Prev; 2016; 17(9):4391-4394. PubMed ID: 27797249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
    Zhu LB; Xu Q; Hong CY; Yue Z; Zhang Y; Ye HN; Yuan Y
    Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.